📢 Important Update: The national procurement agreement's metric for DOACs has evolved.

Previously, Edoxaban was the most cost-effective option. Now, with the unexpected early authorisation of generic Apixaban in the UK – a result of extensive legal discussions – Apixaban has become more affordable than other DOACs.

Consequently, NHS England has revised their commissioning guidelines to align with this development. 💷🔁 #HealthcareUpdates #CostEffectiveCare

https://www.england.nhs.uk/long-read/commissioning-recommendations-for-national-procurement-for-doacs/